论文部分内容阅读
目的观察孟鲁司特钠对婴幼儿毛细支气管炎的临床疗效以及对反复喘息的预防效果。方法将232例年龄为6～12个月的毛细支气管炎患儿随机分治疗组(n=120)和常规组(n=112)。治疗组在常规治疗的基础上加服孟鲁司特钠颗粒4mg,每晚1次,共3个月。观察各组患儿喘息、咳嗽及肺部哮鸣音的变化,记录喘息缓解、肺部哮鸣音消失及咳嗽消失所需时间;住院第1天及第7天查外周血中嗜酸性粒细胞计数;所有病例均随访1a,统计1a内喘息复发的人数。结果治疗组喘息缓解、肺部哮鸣音消失、咳嗽消失天数均少于常规组,差异有高度统计学意义(P<0.01),治疗组在住院第7天时血嗜酸性粒细胞计数较入院时降低,差异有高度统计学意义(P<0.01);常规组差异均无统计学意义(P>0.05)。治疗组1a内喘息复发作人数明显少于常规组,差异有高度统计学意义(P<0.01)。结论早期口服孟鲁司特钠治疗毛细支气管炎可以有效改善症状和体征,缩短病程;降低血嗜酸性粒细胞计数;减少婴幼儿喘息复发。
Objective To observe the clinical efficacy of montelukast sodium on bronchiolitis in infants and young children and the preventive effect on recurrent wheezing. Methods A total of 232 children with bronchiolitis aged 6 to 12 months were randomized to receive treatment (n = 120) and conventional (n = 112). Treatment group on the basis of conventional treatment plus service montelukast sodium particles 4mg, 1 night, a total of 3 months. Observe wheezing, cough and lung wheeze changes in each group, record wheeze relief, disappearance of lung wheeze and cough disappear time; on the first day and 7 days after admission, check the peripheral blood eosinophils Count; all cases were followed up 1a, the statistics of the number of recurrence of wheezing in 1a. Results In the treatment group, wheezing relief, disappearance of lung wheeze and days of cough disappearing were all less than those in the conventional group (P <0.01). In the treatment group, blood eosinophil count was higher on the 7th day (P <0.01). There was no significant difference in the conventional group (P> 0.05). The number of recurrent wheezing in treatment group 1a was significantly less than that in conventional group, the difference was highly statistically significant (P <0.01). Conclusion Early oral montelukast sodium treatment of bronchiolitis can effectively improve the symptoms and signs, shorten the course of the disease; reduce blood eosinophil count; reduce infant wheezing relapse.